What are the symptoms and treatment options for osteoporosis, particularly in older adults and postmenopausal women with a family history of the condition?

Osteoporosis Symptoms and Clinical Presentation

Osteoporosis is typically asymptomatic until a fracture occurs—the disease itself produces no symptoms, making it a "silent disease" that requires proactive screening rather than waiting for clinical manifestations. 1

Clinical Presentation

The Asymptomatic Nature

• Osteoporosis produces no symptoms in its uncomplicated state—patients have no pain, no functional limitations, and no awareness of progressive bone loss until the first fracture occurs 2, 3
• The disease is diagnosed either by bone mineral density (BMD) testing showing a T-score ≤ -2.5 at the femoral neck or lumbar spine, or by the occurrence of a fragility fracture 1

When Symptoms Appear: Fracture Complications

• Clinical symptoms only manifest when osteoporosis is complicated by fracture, which represents a sentinel event indicating severe bone fragility 3
• Vertebral fractures (the most common osteoporotic fracture) may present with acute back pain after minimal trauma, or may be discovered incidentally on imaging as asymptomatic morphometric fractures 4, 2
• Hip fractures present with inability to bear weight, severe hip/groin pain, and inability to ambulate after a fall from standing height 4
• Nonvertebral fractures (wrist, humerus, ribs, pelvis) typically occur after falls from standing height and present with localized pain and functional impairment 4

Post-Fracture Sequelae

• Vertebral fractures are associated with chronic back pain, height loss, kyphosis (dowager's hump), and reduced quality of life 2, 3
• Hip fractures carry substantial morbidity and mortality, with many patients losing independence and requiring long-term care 2, 5

Risk Factors Warranting Screening (Not Symptoms)

Since osteoporosis is asymptomatic, identification relies on recognizing risk factors in your patient population:

Major Risk Factors

• Age and sex: Women ≥65 years and men ≥70 years should be screened regardless of other factors 1, 5
• Postmenopausal status in women, particularly with early menopause or premature ovarian failure 1
• Family history: Parental history of hip fracture significantly increases risk 1, 2
• Previous fracture: Any fragility fracture after age 50 increases risk 5-fold for vertebral fractures and 2-3 fold for other sites 1, 3

Additional Risk Factors

• Low body weight (BMI <20 kg/m²) or significant weight loss 1, 2
• Glucocorticoid use: Daily prednisone ≥7.5 mg equivalent for ≥3 months 1, 6
• Lifestyle factors: Current smoking, excessive alcohol (≥3 drinks daily) 1, 2
• Medical conditions: Rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, chronic liver disease, hypogonadism 1, 2, 7
• Medications: Aromatase inhibitors, androgen deprivation therapy, anticonvulsants, anticoagulants 8, 1

Screening Recommendations

Who to Screen

• All postmenopausal women ≥65 years should undergo DXA screening 8, 1, 5
• Younger postmenopausal women with clinical risk factors (family history, low body weight, smoking, prior fracture, glucocorticoid use) 8, 1
• Men ≥70 years per Bone Health and Osteoporosis Foundation (though USPSTF found insufficient evidence for routine male screening) 5
• Postmenopausal breast cancer survivors should have baseline DXA, with repeat scans every 2 years if on aromatase inhibitors 8

Diagnostic Criteria

• Osteoporosis: T-score ≤ -2.5 at femoral neck or lumbar spine, OR presence of fragility fracture 1, 2
• Osteopenia (low bone mass): T-score between -1.0 and -2.5 4, 9, 10

Treatment Approach for Your High-Risk Population

Postmenopausal Women with Family History and Osteoporosis

For women with confirmed osteoporosis (T-score ≤ -2.5 or prior fragility fracture), initiate pharmacologic treatment with oral bisphosphonates as first-line therapy. 4, 1, 6

First-Line Pharmacologic Treatment

• Alendronate 70 mg once weekly OR risedronate 35 mg once weekly are the preferred initial agents 4, 1, 6
• Alternative: Zoledronic acid 5 mg IV annually for patients intolerant of oral bisphosphonates 4, 1
• Alternative: Denosumab 60 mg subcutaneously every 6 months if bisphosphonates are contraindicated 4, 1, 11
• Treatment duration: Plan for 5 years initially, then reassess fracture risk to determine if continuation is warranted 4, 1, 9

Very High-Risk Patients

• Consider anabolic agents first (teriparatide, abaloparatide, romosozumab) for patients with recent vertebral fractures, hip fracture with T-score ≤ -2.5, or multiple fractures, followed by antiresorptive therapy 2, 5, 12

Avoid These Medications

• Do NOT use menopausal estrogen therapy, estrogen plus progestogen, or raloxifene for osteoporosis treatment—harms outweigh benefits 1

Universal Non-Pharmacologic Interventions

All patients with osteoporosis or osteopenia should receive:

• Calcium supplementation: 1,000-1,200 mg daily total intake (diet plus supplements) 8, 9, 10, 2
• Vitamin D supplementation: 600-800 IU daily (up to 2,000 IU may be needed in deficient patients) 8, 9, 10, 2
• Weight-bearing exercise: Walking, jogging, stair climbing combined with resistance training 8, 9, 10, 2
• Balance training: To reduce fall risk (heel raises, standing on one foot, tai chi) 9, 2
• Smoking cessation and alcohol limitation (≤2 drinks daily) 1, 10, 2

Monitoring During Treatment

• Do NOT monitor BMD during the initial 5-year treatment period with bisphosphonates—it does not change management and is not cost-effective 1, 9
• Reassess fracture risk after 5 years to determine if continued therapy is needed 1, 9
• For untreated osteopenic patients, repeat DXA every 2 years 9

Critical Pitfalls to Avoid

Special Population: Advanced Chronic Kidney Disease

• Patients with eGFR <30 mL/min/1.73 m² are at high risk for severe, life-threatening hypocalcemia with denosumab 11
• These patients require evaluation for chronic kidney disease-mineral bone disorder (CKD-MBD) with intact PTH, serum calcium, and vitamin D levels before initiating denosumab 11
• Treatment should be supervised by a provider with CKD-MBD expertise 11

Pregnancy Considerations

• Pregnancy must be ruled out before initiating denosumab in all women of reproductive potential—the drug can cause fetal harm 11

Secondary Causes

• Evaluate for secondary causes of osteoporosis with CBC, comprehensive metabolic panel, and 25-hydroxyvitamin D level—secondary causes are present in 44-90% of patients with low BMD 13
• Common secondary causes include hypogonadism (40-60% in men), glucocorticoid use, and estrogen deficiency in premenopausal women 13